20 results
8-K
EX-99.1
GLYC
GlycoMimetics Inc
27 Mar 24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
9:00am
-making.
Corporate Update
GlycoMimetics strengthened its leadership team by appointing Shantha Tyavanagimatt, Ph.D., as Senior Vice President
PRE 14A
GLYC
GlycoMimetics Inc
22 Mar 24
Preliminary proxy
5:00pm
and characteristics, leadership traits, work ethic, and independence to provide effective oversight. No director or executive officer is related by blood, marriage … as one of our co-founders and her experience with biotechnology companies prior to founding our company, in addition to her leadership skills, allow
8-K
EX-99.1
GLYC
GlycoMimetics Inc
1 Mar 24
Regulation FD Disclosure
9:16am
developed for self-administration at time of VOC Galectins Targeting fibrotic diseases First oral Galectin-3 antagonist Multiple Key Leadership Hires in Last
8-K
EX-99.1
kgp9 n7cqvidz4xu
4 Oct 22
Regulation FD Disclosure
5:03pm
8-K
EX-99.2
tnwbdp1g nezowba
5 Aug 21
Glycomimetics Reports Highlights and Financial Results
8:01am
8-K
EX-99.1
titszy79 567k
7 Jan 20
GLYCOMIMETICS AND APOLLOMICS Announce Exclusive Collaboration and License Agreement to Develop and Commercialize UPROLESELAN and GMI-1687
4:00pm
8-K
EX-99.1
agig3l 28s
5 Mar 19
Glycomimetics Announces Transition Plan for Board of Directors
5:24pm
8-K
EX-99.1
jr9vn lb54e0kla
28 Nov 18
Scott Jackson, Veteran Biopharmaceutical Executive, Joins Glycomimetics Board of Directors
4:00pm
10-K
qx19trccaxkxqvm
31 Mar 14
Annual report
12:00am
424B4
iv3r09bggirxjr zm
10 Jan 14
Prospectus supplement with pricing info
12:00am
S-1
mky996kfxsu6kod fcjx
4 Oct 13
IPO registration
12:00am
- Prev
- 1
- Next